Want to see HK:1276 full AI Analyst Report?
Total Valuation
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has a market cap or net worth of HK$350.30B. The enterprise value is HK$338.39K.
Market CapHK$350.30B
Enterprise ValueHK$338.39K
Share Statistics
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding258,197,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 12.55%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.11
Return on Invested Capital (ROIC)12.55%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.71M
Profits Per Employee416.72K
Employee Count20,602
Asset Turnover0.45
Inventory Turnover1.52
Valuation Ratios
The current PE Ratio of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H is 40.0. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s PEG ratio is 2.21.
PE Ratio40.0
PS Ratio13.15
PB Ratio6.79
Price to Fair Value6.79
Price to FCF50.27
Price to Operating Cash Flow34.77
PEG Ratio2.21
Income Statement
In the last 12 months, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H had revenue of 35.19B and earned 8.58B in profits. Earnings per share was 1.32.
Revenue35.19B
Gross Profit30.33B
Operating Income10.00B
Pretax Income9.69B
Net Income8.58B
EBITDA10.64B
Earnings Per Share (EPS)1.32
Cash Flow
In the last 12 months, operating cash flow was 10.01B and capital expenditures -3.70B, giving a free cash flow of 6.32B billion.
Operating Cash Flow10.01B
Free Cash Flow6.32B
Free Cash Flow per Share24.47
Dividends & Yields
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pays an annual dividend of HK$0.228, resulting in a dividend yield of 0.45%
Dividend Per ShareHK$0.228
Dividend Yield0.45%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.59
52-Week Price Change-43.27%
50-Day Moving Average50.47
200-Day Moving Average61.58
Relative Strength Index (RSI)57.78
Average Volume (3m)5.57M
Important Dates
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H upcoming earnings date is Oct 23, 2026, TBA (Confirmed).
Last Earnings DateAug 19, 2026
Next Earnings DateOct 23, 2026
Ex-Dividend Date―
Financial Position
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H as a current ratio of 8.08, with Debt / Equity ratio of 1.12%
Current Ratio8.08
Quick Ratio7.63
Debt to Market Cap0.00
Net Debt to EBITDA-4.28
Interest Coverage Ratio626.53
Taxes
In the past 12 months, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has paid 1.10B in taxes.
Income Tax1.10B
Effective Tax Rate0.11
Enterprise Valuation
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H EV to EBITDA ratio is 39.19, with an EV/FCF ratio of 45.32.
EV to Sales11.85
EV to EBITDA39.19
EV to Free Cash Flow45.32
EV to Operating Cash Flow33.37
Balance Sheet
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has HK$44.89B in cash and marketable securities with HK$836.30M in debt, giving a net cash position of HK$44.05B billion.
Cash & Marketable SecuritiesHK$44.89B
Total DebtHK$836.30M
Net CashHK$44.05B
Net Cash Per ShareHK$170.62
Tangible Book Value Per ShareHK$9.44
Margins
Gross margin is 85.34%, with operating margin of 28.42%, and net profit margin of 24.38%.
Gross Margin85.34%
Operating Margin28.42%
Pretax Margin27.53%
Net Profit Margin24.38%
EBITDA Margin30.25%
EBIT Margin27.58%
Analyst Forecast
The average price target for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H is HK$81.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$81.63
Price Target Upside75.54% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast7.52%
EPS Growth Forecast―